Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT(TM)-LYM Trial of CTX130(TM) in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

GlobeNewswire June 11, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Business Wire June 11, 2022

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

GlobeNewswire June 8, 2022

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001(TM) at the 2022 Annual European Hematology Association (EHA) Congress

Business Wire June 2, 2022

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

GlobeNewswire May 31, 2022

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

GlobeNewswire May 16, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130(TM) for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

GlobeNewswire May 12, 2022

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

GlobeNewswire May 4, 2022

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire April 12, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire April 7, 2022

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

GlobeNewswire March 8, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 28, 2022

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 15, 2022

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 9, 2022

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

GlobeNewswire February 2, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 23, 2021

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110(TM) for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

GlobeNewswire November 22, 2021

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

GlobeNewswire November 16, 2021

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 3, 2021